Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Negative 83.0%

Neg 83% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $49 to $48.